PEPTIDE GUIDE

What Is PTD-DBM?

PTD-DBM is an experimental peptide designed to interrupt an interaction between two proteins called CXXC5 and Dishevelled. That interaction applies a brake to Wnt and beta-catenin signalling, a communication system involved in hair-follicle activity, skin repair and many other biological processes.

The name describes its two functional parts. PTD means protein transduction domain, a segment intended to help the molecule cross cell membranes. DBM means Dishevelled-binding motif, a segment that competes with CXXC5 for a binding site on Dishevelled.

Researchers have studied PTD-DBM in cultured cells, isolated hair follicles and mice. They have not published a trial in which people received it for hair loss, wound healing or any other condition. PTD-DBM is not an approved medicine.

Research statusPreclinical hair and wound research; no published human treatment study
Compound typeExperimental cell-penetrating competitor peptide
Human evidenceNo published human treatment study
ApprovalNot approved
Last reviewedOctober 2026
THE SHORT ANSWER

PTD-DBM is a laboratory-designed competitor peptide that releases one molecular brake on Wnt and beta-catenin signalling. Studies have reported increased activity in human hair-follicle dermal papilla cells, faster hair regrowth in mice and the formation of new follicles in wounded mouse skin. Human balding scalp samples helped researchers identify high CXXC5 levels in miniaturised follicles, but the samples were not a treatment experiment. There is no published evidence that applying or administering PTD-DBM regrows hair safely in people. Its absorption, durability, long-term safety and possible effects outside hair follicles remain unknown.

What is PTD-DBM made to do?

CXXC5 is a regulatory protein. After the Wnt pathway becomes active, CXXC5 can bind Dishevelled, often shortened to Dvl, and reduce further signalling. This negative-feedback loop helps prevent a biological signal from remaining switched on indefinitely.

PTD-DBM was designed to occupy the relevant Dishevelled binding surface. In the experimental model, CXXC5 can no longer attach as effectively, so beta-catenin accumulates and reaches the cell nucleus. There it can influence genes associated with cell growth and hair-follicle development.

This mechanism is more specific than saying the peptide simply “activates hair growth”. Wnt signalling acts in many tissues and participates in development, stem-cell behaviour and some cancers. A change in a signalling marker does not by itself establish useful or safe hair regrowth.

Why did researchers study CXXC5 in hair follicles?

The 2017 study compared scalp samples from balding and non-balding areas. CXXC5 was more abundant in miniaturised follicles from balding scalp. Miniaturisation is the process in androgenetic alopecia, or pattern hair loss, in which follicles progressively produce finer and shorter hairs.

The study also used mice genetically altered not to produce CXXC5. Their hair returned more quickly after removal, and wounded skin produced more new follicles. These findings supported CXXC5 as a regulator, but genetically removing a protein throughout a mouse is not equivalent to treating a person's scalp with a peptide.

What did the cell experiments show?

Researchers used human dermal papilla cells, specialised cells at the base of a hair follicle that help control its growth cycle. CXXC5 reduced alkaline phosphatase activity and cell proliferation. Alkaline phosphatase is an enzyme commonly used as a marker of active dermal papilla cells.

PTD-DBM interfered with the CXXC5 and Dishevelled interaction. When researchers combined it with Wnt3a, a Wnt signalling protein, or valproic acid, a medicine that can increase beta-catenin signalling through another route, the measured cell responses increased further.

These were controlled laboratory conditions. Cell proliferation and enzyme activity are mechanistic results, not proof of denser hair, improved appearance or acceptable safety in people. The combination findings also do not support combining unapproved material with valproic acid, which is a prescription medicine with serious risks.

What did the mouse hair studies find?

In C3H mice, a strain commonly used for hair-cycle research, topical experimental treatment accelerated visible hair regrowth after the hair was removed. PTD-DBM and valproic acid together produced stronger signals than either intervention alone in several experiments.

Researchers also studied wound-induced hair neogenesis. This is the formation of new follicles in the centre of a sufficiently large skin wound in certain mice. PTD-DBM increased the number of newly formed follicles in that model.

Mouse skin, hair cycling and wound responses differ from those of human scalp. The wound model does not reproduce ordinary pattern hair loss, and a topical concentration used on mouse skin cannot be converted into a human treatment recommendation.

What did the later hormone study add?

A 2023 paper explored links among dihydrotestosterone, prostaglandin D2 and CXXC5. Dihydrotestosterone is an androgen hormone central to pattern hair loss in genetically susceptible follicles. Prostaglandin D2 is a lipid signal reported at higher levels in balding scalp.

In cultured follicles and mouse models, these signals were associated with higher CXXC5 and lower beta-catenin activity. PTD-DBM or genetic loss of CXXC5 countered some hair suppression caused by prostaglandin D2. This refines a possible pathway but remains preclinical.

Has PTD-DBM been studied for wound healing?

Earlier work found reduced CXXC5 in cells at the edge of acute human wounds and examined the protein in mouse repair. Blocking the CXXC5 and Dishevelled interaction with PTD-DBM increased beta-catenin signalling and collagen production in laboratory and mouse experiments. Combination experiments reported faster closure of mouse wounds.

Collagen is a structural protein that helps form repaired tissue. More collagen or faster closure in a mouse does not show that the peptide prevents infection, produces stronger scars or improves healing in patients. No controlled human wound trial has established those outcomes.

How was PTD-DBM developed?

PeriodDevelopment
Before 2015Researchers established the importance of Wnt and beta-catenin signalling in skin and hair-follicle biology
2015A study described CXXC5 as a negative regulator in wound healing and used PTD-DBM experimentally
2017Cell, human tissue and mouse work connected CXXC5 inhibition with hair regrowth and new follicle formation
2023Mouse and follicle research linked CXXC5 with dihydrotestosterone and prostaglandin D2 signalling
Current positionPreclinical research compound with no published human treatment trial

The programme has not produced a published Phase I study. Phase I is the first clinical stage used to characterise exposure, early safety and how the body handles an investigational medicine.

How is PTD-DBM synthesised and checked?

A research peptide of this type can be assembled by solid-phase peptide synthesis. Protected amino acids are attached one at a time to a growing chain held on a resin. Protecting groups prevent unwanted reactions. The completed chain is released from the resin, deprotected, purified and tested.

Because PTD-DBM joins a cell-penetrating segment to a binding motif, testing needs to confirm the full sequence and exclude shortened chains. Mass spectrometry can check molecular mass, while chromatography separates the intended peptide from related impurities. Peptide content, counterions, water and aggregation may also need measurement.

Material intended for a regulated sterile study would require further controls for identity, potency, batch consistency, particles, bacterial endotoxins, sterility and stability. A supplier's purity number does not answer all of those questions. This description explains manufacture without providing a production recipe.

What is known about safety?

There is no published human exposure study defining common side effects, uncommon harms or a safe exposure range. Topical use would still require evidence about passage through the skin, local irritation, immune reactions and how much intact peptide reaches the circulation.

Wnt and beta-catenin signalling helps maintain tissues but can also support unwanted cell growth when abnormally regulated. The mouse papers did not establish a human cancer risk, yet limited short experiments cannot exclude one. Researchers would also need to examine effects on wound scarring, pigmentation, follicles outside the target area and other organs.

Is PTD-DBM approved?

No. PTD-DBM is not approved by the United States Food and Drug Administration, the United Kingdom Medicines and Healthcare products Regulatory Agency or the European Medicines Agency. It should not be described as a hair-loss treatment on the strength of cell and mouse work.

How strong is the evidence overall?

QuestionBest available evidenceDefensible conclusion
Does PTD-DBM interrupt CXXC5 binding?Protein and cell experimentsSupported in the studied systems
Does it affect human hair-follicle cells?Cultured dermal papilla cellsLaboratory activity was reported
Does it regrow hair?Mouse modelsHair regrowth increased in mice
Does it treat human pattern hair loss?No treatment trialUnknown
Is it safe in people?No human exposure studyUnknown
Is it approved?No regulatory approvalNo
FREQUENTLY ASKED QUESTIONS

Frequently asked questions

What does PTD-DBM stand for?

Protein transduction domain–Dishevelled-binding motif. The first part helps cell entry; the second competes for a protein-binding site.

Is PTD-DBM a natural peptide?

No. It is a laboratory-designed construct based on functional protein segments.

Does PTD-DBM block DHT?

No. Research places it downstream of hormone-related signalling at the CXXC5 and Dishevelled interaction.

Does PTD-DBM regrow human hair?

That has not been shown. Hair regrowth has been reported in mice, not in a human treatment trial.

Were human scalp samples studied?

Yes. Researchers compared protein patterns in scalp tissue, but they did not treat those people with PTD-DBM.

Is it the same as minoxidil or finasteride?

No. Those are established medicines with different mechanisms and human clinical evidence.

Does PTD-DBM heal wounds?

It affected repair measures in cells and mice. Human wound healing has not been established.

Has PTD-DBM completed Phase I testing?

No published Phase I trial was identified.

Is PTD-DBM known to be safe?

No. A human safety profile has not been established.

Is PTD-DBM approved?

No. It is not an approved medicine.

Research reviewed through October 2026.